v3.26.3
CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)
$ in Thousands
Total
Series A Preferred Stock
Common stock
Common stock
Series A Preferred Stock
Additional paid-in capital
Additional paid-in capital
Series A Preferred Stock
Accumulated deficit
Beginning balance (in shares) at Dec. 31, 2025 14,516,188            
Beginning balance at Dec. 31, 2025 $ 99,850            
Ending balance (in shares) at Mar. 31, 2026 14,516,188            
Ending balance at Mar. 31, 2026 $ 99,850            
Beginning balance (in shares) at Dec. 31, 2025 3,047,675   3,047,675        
Beginning balance at Dec. 31, 2025 $ (70,990)   $ 0   $ 4   $ (70,994)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Stock-based compensation 308       308    
Net loss (2,745)           (2,745)
Ending balance (in shares) at Mar. 31, 2026     3,047,675        
Ending balance at Mar. 31, 2026 $ (73,427)   $ 0   312   (73,739)
Beginning balance (in shares) at Dec. 31, 2025 14,516,188            
Beginning balance at Dec. 31, 2025 $ 99,850            
Ending balance (in shares) at Sep. 30, 2026 0            
Ending balance at Sep. 30, 2026 $ 0            
Beginning balance (in shares) at Dec. 31, 2025 3,047,675   3,047,675        
Beginning balance at Dec. 31, 2025 $ (70,990)   $ 0   4   (70,994)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net loss $ (18,981)            
Ending balance (in shares) at Sep. 30, 2026 11,473,285   11,473,285        
Ending balance at Sep. 30, 2026 $ 267,518   $ 1   357,492   (89,975)
Beginning balance (in shares) at Mar. 31, 2026 14,516,188            
Beginning balance at Mar. 31, 2026 $ 99,850            
Ending balance (in shares) at Jun. 30, 2026 14,516,188            
Ending balance at Jun. 30, 2026 $ 99,850            
Beginning balance (in shares) at Mar. 31, 2026     3,047,675        
Beginning balance at Mar. 31, 2026 (73,427)   $ 0   312   (73,739)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Stock-based compensation 505       505    
Net loss (6,512)           (6,512)
Ending balance (in shares) at Jun. 30, 2026     3,047,675        
Ending balance at Jun. 30, 2026 $ (79,434)   $ 0   817   (80,251)
Mezzanine equity              
Conversion of Series A convertible preferred stock into common stock and pre-funded warrants upon the closing of the reverse recapitalization (in shares)   (14,516,188)          
Conversion of Series A convertible preferred stock into common stock and pre-funded warrants upon the closing of the reverse recapitalization   $ (99,850)          
Ending balance (in shares) at Sep. 30, 2026 0            
Ending balance at Sep. 30, 2026 $ 0            
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Stock-based compensation 705       705    
Net loss (9,724)           (9,724)
Conversion of common stock into pre-funded warrants upon close of the reverse recapitalization (in shares)     (2,915,531)        
Conversion of Series A convertible preferred stock into common stock and pre-funded warrants upon the closing of the reverse recapitalization (in shares)       1,175,836      
Conversion of Series A convertible preferred stock into common stock and pre-funded warrants upon the closing of the reverse recapitalization   $ 99,850       $ 99,850  
Issuance of common stock and pre-funded warrants in the Yarrow Pre-Closing Financing (in shares)     822,751        
Issuance of common stock and pre-funded warrants in the Yarrow Pre-Closing Financing 99,955       99,955    
Issuance costs of Pre-Closing financing and reverse recapitalization (2,899)       (2,899)    
Issuance of common stock to former stockholders of VYNE in connection with the closing of the reverse recapitalization (in shares)     672,305        
Issuance of common stock to former stockholders of VYNE in connection with the closing of the reverse recapitalization (2,589)       (2,589)    
Return of investor shares in exchange for pre-funded warrants (in shares)     (133,290)        
Issuance of common stock upon exercise of pre-funded warrants (in shares)     2,168,924        
Issuance of common stock under the September 2026 Offering, net of transaction costs (in shares)     6,634,615        
Issuance of common stock under the September 2026 Offering, net of transaction costs $ 161,654   $ 1   161,653    
Ending balance (in shares) at Sep. 30, 2026 11,473,285   11,473,285        
Ending balance at Sep. 30, 2026 $ 267,518   $ 1   $ 357,492   $ (89,975)